SciSparc Ltd. SPRC
Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
SciSparc Ltd. is an Israel-based clinical-stage pharmaceutical company focused on developing cannabinoid-based therapies for disorders involving the central nervous system and other unmet medical needs. The company operates within the biotechnology and specialty pharmaceutical industries, with research centered on combinations of cannabinoids and other pharmaceutical compounds intended to improve efficacy or reduce side effects associated with conventional therapies. SciSparc’s primary value drivers are its proprietary drug-development programs, intellectual property portfolio, and clinical and preclinical research collaborations.
The company’s principal development programs have included therapies targeting Tourette syndrome, autism spectrum disorder and status epilepticus, as well as technologies involving cannabinoid-based formulations. SciSparc has also pursued development initiatives involving psychedelic-related technologies and pharmaceutical combinations through affiliated entities and investments. Originally established as Therapix Biosciences Ltd., the company later rebranded to SciSparc Ltd. as part of a broader strategic repositioning focused on cannabinoid pharmaceutical development and diversified neuropsychiatric therapeutics.
Business Operations
SciSparc generates activity primarily through pharmaceutical research and development rather than commercial product sales. Its operations have centered on advancing clinical and preclinical programs through partnerships with academic institutions, contract research organizations, and biotechnology collaborators. Key development assets have included cannabinoid-based therapeutic candidates such as SCI-110 and SCI-160, alongside additional proprietary formulations intended for neurological and psychiatric indications. The company has historically relied on equity financing, strategic investments, and licensing arrangements to support operations, consistent with many clinical-stage biotechnology companies.
SciSparc operates internationally but maintains a relatively concentrated operational structure compared with larger pharmaceutical companies. The company’s activities have included collaborations and investments involving entities connected to pharmaceutical technology, nutraceutical development, and cannabinoid research. Public disclosures have referenced relationships involving MitoCareX Bio Ltd. and other affiliated ventures tied to emerging therapeutic technologies. Data regarding long-term revenue diversification remains limited because the company has not yet established broad commercial pharmaceutical distribution operations based on publicly available filings.
Strategic Position & Investments
SciSparc’s strategic direction has emphasized expanding intellectual property and pursuing differentiated therapies involving cannabinoids, combination-drug approaches, and neuropsychiatric treatment platforms. The company has sought to position itself within specialized therapeutic niches where conventional treatment options may be limited or associated with significant side effects. Its development strategy has also included pursuing orphan or difficult-to-treat indications that may support accelerated regulatory pathways or specialized commercialization opportunities.
The company has announced investments and strategic transactions involving biotechnology and pharmaceutical innovation platforms, including exposure to psychedelic-related technologies and nutraceutical research initiatives. SciSparc has also pursued acquisitions and equity investments intended to broaden its pipeline and technology portfolio. Public filings and corporate announcements indicate an emphasis on expanding proprietary formulations and strengthening intellectual property protections. Some strategic initiatives remain at early development stages, and certain commercial outcomes are not yet independently verifiable through long-term operational results. Data inconclusive based on available public sources regarding the future financial impact of several early-stage investments.
Geographic Footprint
SciSparc is headquartered in Tel Aviv, Israel, and its shares trade on the Nasdaq Capital Market under the ticker SPRC. The company’s research, regulatory, and partnership activities have included operations and collaborations in Israel, the United States, and parts of Europe. Its clinical and scientific activities have historically relied on international research institutions and external development partners rather than large-scale owned manufacturing infrastructure.
The company’s market visibility is strongest in the North American capital markets due to its Nasdaq listing, while its operational roots remain tied to the Israeli biotechnology ecosystem. SciSparc’s strategic partnerships and intellectual property initiatives reflect a cross-border operating model common among smaller biotechnology firms seeking access to global research talent, regulatory pathways, and investment capital.
Leadership & Governance
SciSparc’s leadership has emphasized advancing cannabinoid-based pharmaceutical innovation through clinical development, intellectual property expansion, and strategic collaborations. The company’s governance structure reflects a typical publicly traded biotechnology organization with executive leadership overseeing scientific development, financing activities, regulatory strategy, and investor relations. Public company disclosures, including SEC filings, indicate that management has prioritized pipeline advancement and partnership-driven growth while maintaining access to public capital markets.
Key executives and directors associated with SciSparc have included:
- Oz Adler – Chief Executive Officer
- Prof. Raphael Mechoulam – Scientific Advisor and cannabinoid research pioneer
- Yael Goldfain – Chief Financial Officer
- Miriam Ben Dror – Director
- Avi Alroy – Chairman of the Board
Leadership strategy has generally focused on leveraging cannabinoid science, expanding proprietary technologies, and identifying opportunities in neuropsychiatric and specialty therapeutic markets. Certain executive appointments and board compositions have changed over time, and investors typically rely on the company’s latest SEC filings and annual reports for the most current governance information.